Evidence map›Paper›PMID 34640461›Full record

ReviewJournal of clinical medicine2021

A Systematic Review of the Cyclooxygenase-2 (COX-2) Expression in Rectal Cancer Patients Treated with Preoperative Radiotherapy or Radiochemotherapy.

Monika Berbecka, Alicja Forma, Jacek Baj, Marzena Furtak-Niczyporuk, Ryszard Maciejewski, Robert Sitarz

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. PrPEnvironmental science & technology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Radiotherapy resistance: identifying universal biomarkers for various human cancers.Journal of cancer research and clinical oncology · 2022
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Monika BerbeckaDepartment of Normal Anatomy, Medical University of Lublin, 20-090 Lublin, Poland.
Alicja FormaDepartment of Forensic Medicine, Medical University of Lublin, 20-090 Lublin, Poland.ORCID 0000-0001-8714-7627
Jacek BajDepartment of Normal Anatomy, Medical University of Lublin, 20-090 Lublin, Poland.ORCID 0000-0002-1372-8987
Marzena Furtak-NiczyporukDepartment of Public Health, Medical University of Lublin, 20-954 Lublin, Poland.
Ryszard MaciejewskiDepartment of Normal Anatomy, Medical University of Lublin, 20-090 Lublin, Poland.ORCID 0000-0002-2115-9649
Robert SitarzDepartment of Normal Anatomy, Medical University of Lublin, 20-090 Lublin, Poland.ORCID 0000-0001-7267-9516
Medical University of Lublin · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main objective of this systematic review is to investigate the expression level of the cyclooxygenase-2 (COX-2) in rectal cancer treated with either preoperative radiotherapy or radiochemotherapy. In addition, we have summarized the effects of preoperative treatment of rectal cancer with regards to the expression levels of COX-2. A systematic literature review was performed in The Cochrane Library, PubMed, Web of Science, and Scopus databases on 1 January 2021 with the usage of the following search string-(cyclooxygenase-2) OR (COX-2) AND (rectal cancer) AND (preoperative radiochemotherapy) OR (preoperative radiotherapy). Among the 176 included in the analysis, only 13 studies were included for data extraction with a total number of 2095 patients. The results of the analysis are based on the articles concerning the expression of COX-2 in rectal cancer among patients treated with preoperative radiotherapy or radiochemotherapy. A COX-2 expression is an early event involved in rectal cancer development. In cases of negative COX-2 expression, radiotherapy and radiochemotherapy might contribute to the reduction of a local recurrence. Therefore, COX-2 may be considered as a biologic factor while selecting patients for more effective, less time-consuming and less expensive preoperative treatment. However, the utility of the administration of COX-2 inhibitors to patients with COX-2 overexpression, in an attempt to improve the patients' response rate to the neoadjuvant treatment, needs an assessment in further clinical trials.

Indexed as

chemoradiotherapyCOX-2cyclooxygenase-2radiotherapyrectal adenocarcinomarectal cancer

Identifiers

PMID34640461
PMCPMC8509380
OpenAlexW3203992827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.